Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the FaSScinate Trial
|
|
- Melinda Adams
- 6 years ago
- Views:
Transcription
1 Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the FaSScinate Trial D Khanna 1, V Berrocal 1, C Denton 2, A Jahreis 3, H Spotswood 4, C Lin 3, J Siegel 3 and D Furst 5, 1 University of Michigan, Ann Arbor, MI, 2 University College London, Royal Free Hospital, London, United Kingdom, 43 Genentech, South San Francisco, CA, 4 Roche Products Ltd., Welwyn Garden City, United Kingdom, 5 University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
2 Disclosures Dr Furst has consultancy relationships with Actelion,Genentech/Roche,Amgen, Corbus,Cytori,Pfizer.Investigator funding from Amgen,Corbus, NIH.
3 Why a combined response index for Systemic Sclerosis (SSc)? SSc has validated outcomes for individual manifestations SSc is a multisystem disorder Trials have largely been negative or modestly positive Inappropriate pharmacologic targets or poor outcome measures? Combined indices successful in other complex systemic rheumatic diseases: RCTs FDA/EMA approval of new therapies RA-ACR/DAS: joint count, HAQ, APRs, all separate measures SLE-SELENA-SLEDAI: SLEDAI, PhyGA, medication change Vasculitis: BVAS versions are single measures of overall disease We seek approaches to treat the underlying disease; thus, we want measures of overall disease
4
5 Consensus and data-driven methodology Delphi exercise and nominal group consensus meeting to select core items Assessment of psychometric properties of core items using 2 longitudinal dcssc cohorts and consensus meeting to select items for patient profiles Development and rating of patient profiles by experts Development of candidate definitions for response and assessment for performance Selection of top indices based on statistical performance and ranking by experts using OMERACT attributes Test in prospective trial
6 2-Step Process Cardio-pulmonary-renal Worsening? Yes No CRISS Score=0.00 PROCEED to Step 2
7 STEP 1: Expert consensus on definition of a patient who is not-improved during a trial Patient is considered not improved* if he/she develops ANY ONE OF THE FOLLOWING DURING THE TRIAL** RENAL: New scleroderma renal crisis ILD: Decline in forced vital capacity (FVC)% predicted 15% (relative) in established ILD and FVC% predicted below 80% predicted* HEART: New onset of left ventricular failure (defined as left ventricular ejection fraction 45%) requiring treatment* CARDIOPULMONARY: New onset of pulmonary arterial hypertension (PAH) on right heart catheterization requiring treatment*. *Irrespective of improvement in other core items ** Attributable to SSc
8 STEP 2 Step 2 involves computing the predicted probability of improving for each patient using a probability equation that includes change in modified Rodnan skin score, FVC%, HAQ-DI, patient global assessment, and physician global assessment. All changes are absolute change (Time 2 Time baseline ).
9 CRISS score Hypothetical example CRISS calculates the probability of improvement on 0.00 to 1.00 scale for each individual patient where 0.00 is no improvement and 1.00 is marked improvement Probability= Placebo or ineffective drug Probability> 0.40 Effective drug
10 48 week double-blind, placebo-controlled trial of early dcssc 5 years disease duration 15 and 40 mrss units Elevated acute-phase reactants 1:1 randomization Khanna D, et al. Lancet. 2016;387(10038):
11 Statistical analysis Step 1 for CRISS was captured using review of serious adverse event data. Step 2 calculated the CRISS index using the probability equation. Non-parametric Wilcoxon test and proportion z-tests were used to assess whether significant differences exist between the CRISS score in both its continuous and binary form in TCZ and PBO. Analyses utilized all subjects, with missing data imputed using the best-fitting linear mixed model determined through Chi-square significance test on the deviance. The linear mixed models selected included a subject-specific random intercept, an indicator for treatment and a function of time.
12 Change From Baseline in mrss at Week 24 (Primary End Point) & Week 48 (Secondary End Point) PBO 162 mg QW SC TCZ 162 mg QW SC Change (95% CI) From Baseline in mrss Weeks Week 24 Week 48 PBO 162 mg QW SC 1.2 ΔLSM 2.8 ΔLSM (TCZ-PBO): 2.70 (TCZ-PBO): 3.6 TCZ 162 mg QW SC 3.9 p = p = 0.06 CI, confidence interval; LSM, least square means; ΔLSM (TCZ-PBO), difference in LSM between treatment arms. Negative change indicates improvement. Means and 95% CI are from the repeated-measures model.
13 Cumulative Distribution by Absolute Change in % pfvc From Baseline to Week 48 Worsening [decrease in % pfvc ] No Decline [increase in % pfvc ] PBO 162 mg QW SC (n = 31) TCZ 162 mg QW SC (n = 30) p = ( Van Elteren) 84% Patients, % % 20 23%* 0 10%* % pfvc Change From Baseline pfvc, predicted forced vital capacity. *Percentage of patients with 10% worsening in % pfvc. 1
14 2-Step Process Cardio-pulmonary-renal Worsening? Yes: 4 in placebo* 0 in TCZ No CRISS Score=0.00 PROCEED to Step 2 * 1 each developed scleroderma renal crisis, heart failure, worsening ILD and PAH
15 Imputed data in fasscinate study (week 24) TCZ group Mean (SD) N=43 PBO group Mean (SD) N=40 P-value* mrss, 0-51* (6.9) (6.0) 0.28 FVC% predicted (4.6) (2.7) < Weeks HAQ-DI, 0-3* 0.17 (0.60) 0.18 (0.44) 0.93 Patient global assessment, 0-10* (1.78) (2.31) 0.51 Physician global assessment, 0-10* (2.62) (2.47) 0.82 *Negative is improvement
16 Imputed data in fasscinate study (week 48) TCZ group Mean (SD) N=43 PBO group Mean (SD) N=40 P-value* mrss, 0-51* (7.18) -3.0 (5.76) 0.12 FVC% predicted (2.33) (3.48) < Weeks HAQ-DI, 0-3* 0.15 (0.69) 0.23 (0.50) 0.53 Patient global assessment, 0-10* (2.22) (2.26) 0.33 Physician global assessment, 0-10* (2.62) (2.74) 0.03 *Negative is improvement
17 CRISS scores at 24 and 48 weeks CRISS, median [IQR] at 24 wks, Imputed data CRISS, median [IQR] at 48 wks, Imputed data CRISS, median [IQR] at 24 wks, Completers only TCZ PBO** P value 0.19 [0.006; 0.92], N= [0.01; 0.93], N= [0.003; 0.95], N= [0.0001; 0.13], N= [0.0002; 0.16], N= [0.00; 0.10], N= * 0.002* 0.04* CRISS, median [IQR] at 48 wks, Completers only 0.31 [0.008; 0.99], N= [0.00; 0.18], N= * *Using Wilcoxon test as CRISS data is not normally distributed ** there are 4 subjects in the PBO who met step 1 and were given a score of 0.0. One patient each with heart failure, Worsening ILD, SRC, and PAH.
18 CRISS scores vs. individual components at week Individual Measures mrss FVC Pt. Glob MD Glob p= CRISS p= TCZ Placebo TCZ Placebo -6.5 P=0.12 P= P=0.33 P= HAQ-DI:TCZ (0.15) vs. Placebo (0.23) p= CRISS completers CRISS imputed Conclusion: CRISS works best, although FVC and mrss also work
19 CRISS score in TCZ at 48 week Placebo TCZ
20 Correlation coefficients between the CRISS score and individual variables in CRISS 24-weeks 48-weeks Change in mrss Change in FVC% TCZ PBO TCZ PBO -0.76* -0.84* -0.75* -0.73* Change in patient global * assessment Change in physician global -0.45* * assessment Change in HAQ-DI -0.49* * -0.43* *p<0.05 using Pearson correlation coefficient
21 Conclusion In this post-hoc analysis from fasscinate trial, CRISS discriminated TCZ from PBO, supporting its validity in an independent cohort from its development cohort. Although mrss had the highest correlation with CRISS score, pt global assessment, physician global assessment, and HAQ-DI had significant correlations. Lack of correlation with FVC% may be related to nonenrichment of ILD in this trial. In the SLS-I (abstract#726), the correlation between CRISS and FVC% ranged between (<0.05). Current work is ongoing to define clinically important differences for CRISS.
22 Funded by NIH/NIAID and NIH/NIAMS
NOT COPY. Choice of the primary outcome: Pro Lung 03/09/2018. Lung assessment in clinical trials
Choice of the primary outcome: Pro Lung Christopher P. Denton Professor of Experimental Rheumatology Royal Free Hospital and University College London, UK Florence 7 th September 218 Improved clinical
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
More informationUpdate in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates
Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates Review Systemic sclerosis affects approximately 75,000 to 100,000 people in the U.S. and has the highest mortality rate of any autoimmune
More informationHaving a stem cell transplant for scleroderma a patient and doctor perspective
Having a stem cell transplant for scleroderma a patient and doctor perspective Professor Chris Denton, On behalf of an excellent team across UCLPartners Royal Free Hospital and University College London,
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE
More informationTITLE PAGE STUDY REPORT NO
TITLE PAGE STUDY REPORT NO. 1075544 From Final Study Report: RO0452317 - F. Hoffmann-L a Roche Ltd Protocol BO20652 Report Number 1075544 1 PASS INFORMATION TITLE: AN OBSERVATIONAL STUDY OF CARDIAC EVENTS
More informationMeasures of Systemic Sclerosis (Scleroderma)
Arthritis Care & Research Vol. 63, No. S11, November 2011, pp S98 S111 DOI 10.1002/acr.20598 2011, American College of Rheumatology MEASURES OF PATHOLOGY AND SYMPTOMS Measures of Systemic Sclerosis (Scleroderma)
More informationStandardization of modified Rodnan skin score in clinical trials of systemic sclerosis
Standardization of modified Rodnan skin score in clinical trials of systemic sclerosis Dinesh Khanna 1, Daniel E. Furst 2, Philip J. Clements 2, Yannick Allanore 3, Lazlo Czirjak 4, Oliver Distler 5, Ivan
More informationEfficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II
Original Article DOI 10.1002/acr.23282 Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II Rajaie Namas, MD 1, Donald
More informationEfficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.
1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and
More informationDevelopment and initial validation of a composite. response index for clinical trials in early diffuse. cutaneous systemic sclerosis
Development and initial validation of a composite response index for clinical trials in early diffuse cutaneous systemic sclerosis Dinesh Khanna, MD, MS 1, Veronica J. Berrocal, PhD 2, Edward H. Giannini,
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationSafety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (fasscinate): a phase 2, randomised, controlled trial
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (fasscinate): a phase 2, randomised, controlled trial Dinesh Khanna, Christopher P Denton, Angelika Jahreis, Jacob M van
More informationBSR and BHPR guideline for the treatment of systemic sclerosis
BSR and BHPR guideline for the treatment of systemic sclerosis Christopher P. Denton, Michael Hughes, Nataliya Gak, Josephine Vila, Maya Buch, Kuntal Chakravarty, Kim Fligelstone, Luke L Gompels, Bridget
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationTreatment of Scleroderma Informed by Canadian Research
Treatment of Scleroderma Informed by Canadian Research Janet Pope MD MPH FRCPC Professor of Medicine Schulich School of Medicine & Dentistry University of Western Ontario St. Joseph s Health Care London,
More informationMortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationStatistics as a Tool. A set of tools for collecting, organizing, presenting and analyzing numerical facts or observations.
Statistics as a Tool A set of tools for collecting, organizing, presenting and analyzing numerical facts or observations. Descriptive Statistics Numerical facts or observations that are organized describe
More informationMinimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
Khanna et al. Arthritis Research & Therapy (2019) 21:23 https://doi.org/10.1186/s13075-019-1809-y RESEARCH ARTICLE Open Access Minimal Clinically Important Differences for the Modified Rodnan Skin Score:
More informationLongitudinal data monitoring for Child Health Indicators
Longitudinal data monitoring for Child Health Indicators Vincent Were Statistician, Senior Data Manager and Health Economist Kenya Medical Research institute [KEMRI] Presentation at Kenya Paediatric Association
More informationClinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December Reference : NHSCB/A3C/1b
Clinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December 2012 Reference : NHSCB/A3C/1b NHS Commissioning Board Clinical Commissioning Policy Statement: Rituximab
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationDoes the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis
Does the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis Gordon R. DeFoe, CCP, John Pieroni, CCP, Craig S. Warren, CCP, Charles F. Krumholz, CCP,
More informationLearning Objectives 9/9/2013. Hypothesis Testing. Conflicts of Interest. Descriptive statistics: Numerical methods Measures of Central Tendency
Conflicts of Interest I have no conflict of interest to disclose Biostatistics Kevin M. Sowinski, Pharm.D., FCCP Last-Chance Ambulatory Care Webinar Thursday, September 5, 2013 Learning Objectives For
More information9/4/2013. Decision Errors. Hypothesis Testing. Conflicts of Interest. Descriptive statistics: Numerical methods Measures of Central Tendency
Conflicts of Interest I have no conflict of interest to disclose Biostatistics Kevin M. Sowinski, Pharm.D., FCCP Pharmacotherapy Webinar Review Course Tuesday, September 3, 2013 Descriptive statistics:
More informationKey Indexing Terms: OMERACT SCLERODERMA CRISS EPOSS OUTCOMES CLINICAL TRIALS
Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis
More informationUNDERSTANDING THE NEED FOR ASSISTANCE WHEN COMPLETING MEASURES OF PATIENT-REPORTED OUTCOMES IN HUNTINGTON DISEASE
UNDERSTANDING THE NEED FOR ASSISTANCE WHEN COMPLETING MEASURES OF PATIENT-REPORTED OUTCOMES IN HUNTINGTON DISEASE Noelle E. Carlozzi, Ph.D. September 27, 2017 HUNTINGTON DISEASE (HD) https://youtu.be/jzaph2v-scq
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationFEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationClopidogrel and Aspirin in Acute Ischemic Stroke and TIA: Final Results of the POINT Trial
Clopidogrel and Aspirin in Acute Ischemic Stroke and TIA: Final Results of the POINT Trial S. Claiborne Johnston, 1 J. Donald Easton, 2 Mary Farrant, 2 William Barsan, 3 Robin A. Conwit, 4 Jordan J. Elm,
More informationTumor Growth rates to better capture therapeutic activity in cancer patients
Tumor Growth rates to better capture therapeutic activity in cancer patients Charles Ferté MD PhD Statistical and biomedical models for imaging in cancer Apr 2016, 8th - ISPED Serge Koscielny 2 Background
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationΠνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION. Αναστασία Ανθη
Πανελλήνια Σεμινάρια Ομάδων Εργασίας 2017 k Πνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό Ιατρείο Πνευμ. Υπέρτασης Π.Γ.Ν.
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationManagement of Widespread Skin Thickening in Diffuse Systemic Sclerosis
Curr Treat Options in Rheum (2016) 2:49 60 DOI 10.1007/s40674-016-0040-0 Scleroderma (D Khanna, Section Editor) Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis Suzanne Kafaja, MD
More informationChoosing the Correct Statistical Test
Choosing the Correct Statistical Test T racie O. Afifi, PhD Departments of Community Health Sciences & Psychiatry University of Manitoba Department of Community Health Sciences COLLEGE OF MEDICINE, FACULTY
More informationdifferent phenotypes
Pulmonary hypertension in scleroderma: different phenotypes UMR 995 Pr David LAUNAY, MD, PhD launayd@gmail.com Service de Médecine Interne. Unité d'immunologie Clinique CNRMR Maladies Systémiques et Autoimmunes
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationCorporate Update January 2018
Corporate Update January 2018 Tenax Strategic Update Specialty pharmaceutical company focused on search, development, and commercialization of drugs that address diseases with high unmet medical need Shift
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationInternational DErmatology Outcomes Measures. Modeled after OMERACT: Outcomes Measures in Rheumatology
International DErmatology Outcomes Measures Modeled after OMERACT: Outcomes Measures in Rheumatology 1992 original intent: obtain agreement on the minimum number of outcome measures to be included in all
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationMarket Access CTR Summary
Market Access CTR Summary Study No.: BEL114246 Title: Efficacy of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: A Pooled Analysis of the HGS1006-C1056 (BLISS-52)
More informationTOTAL HIP AND KNEE REPLACEMENTS. FISCAL YEAR 2002 DATA July 1, 2001 through June 30, 2002 TECHNICAL NOTES
TOTAL HIP AND KNEE REPLACEMENTS FISCAL YEAR 2002 DATA July 1, 2001 through June 30, 2002 TECHNICAL NOTES The Pennsylvania Health Care Cost Containment Council April 2005 Preface This document serves as
More informationAssessment of Quality of Life Using Skindex-16 in Patients With Locally Advanced Basal Cell Carcinoma Treated With Vismodegib in the STEVIE Study
Assessment of Quality of Life Using Skindex-16 in Patients With Locally Advanced Basal Cell Carcinoma Treated With Vismodegib in the STEVIE Study Jean-Jacques Grob, 1 Karen Bartley, 2 Rainer Kunstfeld,
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Radicava GENERIC NAME edaravone MANUFACTURER MT Pharma America, Inc. DATE OF APPROVAL May 5, 2017 PRODUCT LAUNCH DATE May 5, 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationSCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston
SCLERODERMA 101 Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston TYPES OF SCLERODERMA Localized versus Systemic Two Kinds of Scleroderma Localized Scleroderma Morphea Linear
More informationBEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS
BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior
More informationProtecting the gains: what changes are needed to prevent a reversal of the downward CVD mortality trend?
Protecting the gains: what changes are needed to prevent a reversal of the downward CVD mortality trend? Abstract 117 Jesse D Ortendahl 1, Allison L Diamant 2, Peter P Toth 3, Dasha Cherepanov 1, Amanda
More informationLow-adherence to recommendations from an authoritative Consensus Conference on trials in cgvhd led to overestimation of treatment effect
Low-adherence to recommendations from an authoritative Consensus Conference on trials in cgvhd led to overestimation of treatment effect Giovanni Pomponio, Jacopo Olivieri*, Lucia Manfredi, Laura Postacchini,
More informationAnnual Congress of the European Society of Cardiology Munich, August
Annual Congress of the European Society of Cardiology Munich, August 26 2012 Gas exchange measurements during exercise show early pulmonary arterial hypertension in scleroderma patients Daniel Dumitrescu,
More informationMonitoring of Renal Function in Heart Failure
Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,
More informationInstructions: This form is completed and entered for all participants. Database will skip over sections that do not apply.
Revision of 08/30/2017 Form #102 Page 1 of 6 PVDOMICS STUDY PVD Assessment - Form #102 Instructions: This form is completed and entered for all participants. Database will skip over sections that do not
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationCerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)
Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR) Michael Mack, MD, Michael Acker, MD, Steve Messe, MD For the Cardiothoracic Surgical Trials Network (CTSN) American
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAlpha blockers have no role in renal colic
Alpha blockers have no role in renal colic HARRY WINKLER Director, section of Endourology Kidney stone center Dept.of Urology Sheba Medical Center Financial and Other Disclosures Off-label use of drugs,
More informationMethodology used to develop new ACR-EULAR criteria. Disclosures. Objectives Guiding principles underlying methodology
Methodology used to develop new ACR-EULAR criteria Sindhu Johnson MD PhD Toronto Scleroderma Program University of Toronto Co-convenors Janet Pope Frank van den Hoogen Members Jaap Fransen Sindhu Johnson
More informationSupplementary Online Content
Supplementary Online Content Khanna D, Denton CP, Merkel PA, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized
More information2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationKhanna et al. Arthritis Research & Therapy (2015) 17:372 DOI /s
Khanna et al. Arthritis Research & Therapy (2015) 17:372 DOI 10.1186/s13075-015-0872-2 RESEARCH ARTICLE Open Access Predictors of lung function decline in scleroderma-related interstitial lung disease
More informationGLOSSARY OF GENERAL TERMS
GLOSSARY OF GENERAL TERMS Absolute risk reduction Absolute risk reduction (ARR) is the difference between the event rate in the control group (CER) and the event rate in the treated group (EER). ARR =
More informationCHAPTER - III METHODOLOGY
74 CHAPTER - III METHODOLOGY This study was designed to determine the effectiveness of nurse-led cardiac rehabilitation on adherence and quality of life among patients with heart failure. 3.1. RESEARCH
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationFrailty Ascertainment: Beginning of the pathway to treatment
Frailty Ascertainment: Beginning of the pathway to treatment Karen Bandeen-Roche, Ph.D. Johns Hopkins Older Americans Independence Center Introduction Whither frailty ascertainment? Geronmetrics a.k.a.:
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationMANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE
MANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE Introduction Substantial body of prior CKD clinical data characterizes Bard s unique profile Bard has demonstrated
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationChristopher J. Swearingen, Sarah Kennedy, Jeyanesh R.S. Tambiah. Samumed LLC, San Diego, CA, USA
Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment Christopher J. Swearingen,
More informationEffect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF) Elizabeth Tien, PharmD, BCPS PGY2 Cardiology Pharmacy Resident Moses H. Cone Memorial Hospital Greensboro, NC Kristen Pogue,
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationBenefit - Risk Analysis for Oncology Clinical Trials
PhUSE 2012 PP14 Benefit - Risk Analysis for Oncology Clinical Trials Waseem Jugon, Lovemore Gakava, Littish Dominic and Jayantha Ratnayake Roche Products Ltd, UK ABSTRACT The conventional analysis of safety
More informationHIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD
HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting honorariums or other payments
More informationAcute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial)
Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial) N Engl J Med. Volume 377(23):2240-2252. December 7, 2017 Wednesday, July 11, 2018, 1:00pm ET Guest
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationSurgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018
Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report May 2018 Prepared by the Canadian Cardiovascular Society (CCS)/Canadian Society of Cardiac Surgeons (CSCS) Cardiac
More informationWhich outcome measures in SLE clinical trials best reflect medical judgment?
To cite: Thanou A, Chakravarty E, James JA, et al. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Science & Medicine 2014;1:e000005. doi:10.1136/lupus-2013-000005 Received
More informationDrug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationMarc Frerix 1*, Johannes Stegbauer 2, Alexander Kreuter 3 and Stefan Markus Weiner 4
Frerix et al. Arthritis Research & Therapy 2014, 16:R54 RESEARCH ARTICLE Open Access Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus:
More informationCurrent Status of Outcome Measure Development for Clinical Trials in Systemic Sclerosis. Report from OMERACT 6
Current Status of Outcome Measure Development for Clinical Trials in Systemic Sclerosis. Report from OMERACT 6 PETER A. MERKEL, PHILIP J. CLEMENTS, JOHN D. REVEILLE, MARIAE. SUAREZ-ALMAZOR, GABRIELE VALENTINI,
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More information